Recursion Pharma climbs after 20% staff reduction
Shares of Nvidia-backed AI drug developer Recursion Pharmaceuticals RXRX.O rise 3% to $5.53 premarket
Co says it is laying off 20% of its workforce
RXRX is narrowing its focus to develop drugs for rare diseases and cancers
Recursion's employee count grew from 515 to about 800 in 2024 after merging with Exscientia, according to SEC filing
Co aims to reduce its cash burn to below $450 mln in 2025 and under $390 mln in 2026
Restructuring expected to extend co's cash reserves into late 2027
As of last close, stock down 20.5% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Meme Stocks Reappear. Avis Shares Reach New Highs Amid Short Squeeze. Can Retail Investors Still Buy?

Tesla Q1 2026 Earnings Preview: 50,000-Unit Inventory Overhang, Energy Storage Halved, 5 Core Metrics Long-Term Investors Should Really Watch

AST SpaceMobile Shares Plunge in Overnight Trading, What Happened? Will It Affect SpaceX?

Asia-Pacific Stocks Rise Across the Board Monday as Easing Middle East Tensions Boost Market Sentiment

Intel Stock Has Surged 74% in 2026 and Earnings Land April 23 — Is INTC Still a Buy at $68?

Tradingkey







